Comparison of biological effects of a sustained delivery system and nonencapsulated LH-RH antagonist SB-75 in rats

Jacek Pinski, Tetsu Yano, Kate Groot, Slobodan Milovanovic, Andrew V Schally

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Recently, we developed long-acting microcapsules and microgranules of the LH-RH antagonist SB-75. In this study, we compared the inhibitory effects of a single injection of encapsulated and nonencapsulated LH-RH antagonist SB-75 on gonadotropin and testosterone secretion. The resulting serum SB-75 levels were also measured by RIA. Microgranules containing 4% of this antagonist in poly(dl-lactide-co-glycolide) were administered IM at two different doses (30 and 60 mg/rat) to male rats. Other groups of rats were injected SC with equivalent doses of nonencapsulated SB-75 (1.25 and 2.5 mg/rat). The administration of microgranules at a dose of 60 mg/rat produced a significant elevation of serum SB-75 until day 76, and serum testosterone and LH levels were suppressed below the detection limit of the RIA for a period of 70 days. An equivalent dose of nonencapsulated SB-75 acetate (2.5 mg/rat) produced a significant elevation of SB-75 levels for 20 days and decreased testosterone to castration values and LH levels for merely 21 days. In rats treated with 30 mg microgranules of SB-75 or an equivalent dose of SB-75 acetate (1.25 mg/rat), serum testosterone and LH were suppressed to a similar extent, but for only 2 weeks. In another study, the effect of a single SC injection of 1.25 mg/rat of antagonist SB-75 on pituitary LH-RH receptors was determined, 7 and 60 days after administration. SB-75 produced a significant (p < 0.01) downregulation of membrane receptors for LH-RH 7 days after administration. Our results indicate that the suppression of the pituitary-gonadal axis in rats effected by administration of microgranules of LH-RH antagonist SB-75 is more efficacious than that caused by an equivalent dose of unencapsulated SB-75 and suitable doses of microgranules can maintain elevated levels of SB-75 for several weeks.

Original languageEnglish
Pages (from-to)905-911
Number of pages7
JournalPeptides
Volume13
Issue number5
DOIs
StatePublished - Jan 1 1992
Externally publishedYes

Fingerprint

Gonadotropin-Releasing Hormone
Rats
Testosterone
cetrorelix
Serum
Acetates
LH Receptors
Polyglactin 910
Injections
Castration
Gonadotropins
Capsules
Limit of Detection
Down-Regulation

Keywords

  • LH-RH antagonist
  • Microgranules
  • Pituitary-gonadal axis

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology
  • Physiology
  • Cellular and Molecular Neuroscience

Cite this

Comparison of biological effects of a sustained delivery system and nonencapsulated LH-RH antagonist SB-75 in rats. / Pinski, Jacek; Yano, Tetsu; Groot, Kate; Milovanovic, Slobodan; Schally, Andrew V.

In: Peptides, Vol. 13, No. 5, 01.01.1992, p. 905-911.

Research output: Contribution to journalArticle

Pinski, Jacek ; Yano, Tetsu ; Groot, Kate ; Milovanovic, Slobodan ; Schally, Andrew V. / Comparison of biological effects of a sustained delivery system and nonencapsulated LH-RH antagonist SB-75 in rats. In: Peptides. 1992 ; Vol. 13, No. 5. pp. 905-911.
@article{5405682211db450dad5edbcd185b3db9,
title = "Comparison of biological effects of a sustained delivery system and nonencapsulated LH-RH antagonist SB-75 in rats",
abstract = "Recently, we developed long-acting microcapsules and microgranules of the LH-RH antagonist SB-75. In this study, we compared the inhibitory effects of a single injection of encapsulated and nonencapsulated LH-RH antagonist SB-75 on gonadotropin and testosterone secretion. The resulting serum SB-75 levels were also measured by RIA. Microgranules containing 4{\%} of this antagonist in poly(dl-lactide-co-glycolide) were administered IM at two different doses (30 and 60 mg/rat) to male rats. Other groups of rats were injected SC with equivalent doses of nonencapsulated SB-75 (1.25 and 2.5 mg/rat). The administration of microgranules at a dose of 60 mg/rat produced a significant elevation of serum SB-75 until day 76, and serum testosterone and LH levels were suppressed below the detection limit of the RIA for a period of 70 days. An equivalent dose of nonencapsulated SB-75 acetate (2.5 mg/rat) produced a significant elevation of SB-75 levels for 20 days and decreased testosterone to castration values and LH levels for merely 21 days. In rats treated with 30 mg microgranules of SB-75 or an equivalent dose of SB-75 acetate (1.25 mg/rat), serum testosterone and LH were suppressed to a similar extent, but for only 2 weeks. In another study, the effect of a single SC injection of 1.25 mg/rat of antagonist SB-75 on pituitary LH-RH receptors was determined, 7 and 60 days after administration. SB-75 produced a significant (p < 0.01) downregulation of membrane receptors for LH-RH 7 days after administration. Our results indicate that the suppression of the pituitary-gonadal axis in rats effected by administration of microgranules of LH-RH antagonist SB-75 is more efficacious than that caused by an equivalent dose of unencapsulated SB-75 and suitable doses of microgranules can maintain elevated levels of SB-75 for several weeks.",
keywords = "LH-RH antagonist, Microgranules, Pituitary-gonadal axis",
author = "Jacek Pinski and Tetsu Yano and Kate Groot and Slobodan Milovanovic and Schally, {Andrew V}",
year = "1992",
month = "1",
day = "1",
doi = "10.1016/0196-9781(92)90048-8",
language = "English",
volume = "13",
pages = "905--911",
journal = "Peptides",
issn = "0196-9781",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - Comparison of biological effects of a sustained delivery system and nonencapsulated LH-RH antagonist SB-75 in rats

AU - Pinski, Jacek

AU - Yano, Tetsu

AU - Groot, Kate

AU - Milovanovic, Slobodan

AU - Schally, Andrew V

PY - 1992/1/1

Y1 - 1992/1/1

N2 - Recently, we developed long-acting microcapsules and microgranules of the LH-RH antagonist SB-75. In this study, we compared the inhibitory effects of a single injection of encapsulated and nonencapsulated LH-RH antagonist SB-75 on gonadotropin and testosterone secretion. The resulting serum SB-75 levels were also measured by RIA. Microgranules containing 4% of this antagonist in poly(dl-lactide-co-glycolide) were administered IM at two different doses (30 and 60 mg/rat) to male rats. Other groups of rats were injected SC with equivalent doses of nonencapsulated SB-75 (1.25 and 2.5 mg/rat). The administration of microgranules at a dose of 60 mg/rat produced a significant elevation of serum SB-75 until day 76, and serum testosterone and LH levels were suppressed below the detection limit of the RIA for a period of 70 days. An equivalent dose of nonencapsulated SB-75 acetate (2.5 mg/rat) produced a significant elevation of SB-75 levels for 20 days and decreased testosterone to castration values and LH levels for merely 21 days. In rats treated with 30 mg microgranules of SB-75 or an equivalent dose of SB-75 acetate (1.25 mg/rat), serum testosterone and LH were suppressed to a similar extent, but for only 2 weeks. In another study, the effect of a single SC injection of 1.25 mg/rat of antagonist SB-75 on pituitary LH-RH receptors was determined, 7 and 60 days after administration. SB-75 produced a significant (p < 0.01) downregulation of membrane receptors for LH-RH 7 days after administration. Our results indicate that the suppression of the pituitary-gonadal axis in rats effected by administration of microgranules of LH-RH antagonist SB-75 is more efficacious than that caused by an equivalent dose of unencapsulated SB-75 and suitable doses of microgranules can maintain elevated levels of SB-75 for several weeks.

AB - Recently, we developed long-acting microcapsules and microgranules of the LH-RH antagonist SB-75. In this study, we compared the inhibitory effects of a single injection of encapsulated and nonencapsulated LH-RH antagonist SB-75 on gonadotropin and testosterone secretion. The resulting serum SB-75 levels were also measured by RIA. Microgranules containing 4% of this antagonist in poly(dl-lactide-co-glycolide) were administered IM at two different doses (30 and 60 mg/rat) to male rats. Other groups of rats were injected SC with equivalent doses of nonencapsulated SB-75 (1.25 and 2.5 mg/rat). The administration of microgranules at a dose of 60 mg/rat produced a significant elevation of serum SB-75 until day 76, and serum testosterone and LH levels were suppressed below the detection limit of the RIA for a period of 70 days. An equivalent dose of nonencapsulated SB-75 acetate (2.5 mg/rat) produced a significant elevation of SB-75 levels for 20 days and decreased testosterone to castration values and LH levels for merely 21 days. In rats treated with 30 mg microgranules of SB-75 or an equivalent dose of SB-75 acetate (1.25 mg/rat), serum testosterone and LH were suppressed to a similar extent, but for only 2 weeks. In another study, the effect of a single SC injection of 1.25 mg/rat of antagonist SB-75 on pituitary LH-RH receptors was determined, 7 and 60 days after administration. SB-75 produced a significant (p < 0.01) downregulation of membrane receptors for LH-RH 7 days after administration. Our results indicate that the suppression of the pituitary-gonadal axis in rats effected by administration of microgranules of LH-RH antagonist SB-75 is more efficacious than that caused by an equivalent dose of unencapsulated SB-75 and suitable doses of microgranules can maintain elevated levels of SB-75 for several weeks.

KW - LH-RH antagonist

KW - Microgranules

KW - Pituitary-gonadal axis

UR - http://www.scopus.com/inward/record.url?scp=0026494833&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026494833&partnerID=8YFLogxK

U2 - 10.1016/0196-9781(92)90048-8

DO - 10.1016/0196-9781(92)90048-8

M3 - Article

C2 - 1336188

AN - SCOPUS:0026494833

VL - 13

SP - 905

EP - 911

JO - Peptides

JF - Peptides

SN - 0196-9781

IS - 5

ER -